WASHINGTON (dpa-AFX) - AbbVie (ABBV) Monday announced a collaboration and
option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage
neuroscience biotech firm, to develop next-generation treatment approaches and
unmet needs in psychiatric disorders.

AbbVie noted that the first-generation compounds may induce profound
psychoactive effects, such as hallucinations, necessitating in-office
administration and concomitant supportive care. The discovery of neuroplastogens
might help minimize the challenging effects seen with first-generation
compounds.

These new compounds are intended for treating a variety of psychiatric
conditions, including mood and anxiety disorders.

As per the agreement, AbbVie will lead development and commercialization
activities, upon exercise of the option.

Gilgamesh will receive an upfront payment of $65 million from AbbVie and is
eligible to receive up to $1.95 billion in aggregate option fees and milestones,
as well as tiered royalties from mid-single to low-double digits on net sales.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX